Enzymatic Therapy
Remifemin - 60 Tablets

Safe, estrogen free, natural black cohosh alternative to hormone replacement therapy for menopausal symptoms (763948075003) - 60 Tablets

Remifemin® menopause and perimenopause relief† Safe, estrogen free, natural black cohosh alternative to hormone replacement therapy for menopausal symptoms. Overview Why use a natural menopause formula? More effective than soy. Black cohosh has been proven to be more effective than soy at relieving menopausal symptoms.† For natural relief and a real alternative.† A reliable, clinically-studied black cohosh extract can provide natural relief from hot flashes, night sweats, mood swings.† It allows you to have a strong alternative to Hormone Replacement Therapy (HRT) for the treatment of menopausal symptoms.† Why use Remifemin®? It provides time-tested, estrogen-free relief. Remifemin® provides effective relief for a 70% reduction of hot flashes, night sweats, irritability, mood swings and occasional sleeplessness and anxiety.† In fact, over 15 clinical studies prove it's a safe and effective alternative to HRT for the treatment of menopausal symptoms, thanks to its completely estrogen-free RemiSure™ black cohosh.† Directions One tablet in the morning and one tablet in the evening, with water. You can expect to notice improvements within a few weeks, with full benefits after using Remifemin twice daily for 4-12 weeks. Supplement Facts / Ingredients Amount/Serving %DV Black Cohosh Extract (Root and Rhizome) Equivalent to 20mg * This product does not contain artificial coloring artificial flavoring corn gluten preservatives salt soy wheat yeast This product contains natural ingredients; color variations are normal. Notes CAUTION: Consult your healthcare practitioner prior to use if you are taking prescription drugs. Do not use if pregnant or nursing. Discontinue use and consult a healthcare practitioner if you have a liver disorder or develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice. For a few consumers, gastrointestinal discomfort or allergic reactions may occur but should not be persistent. If you observe these or other side effects, discontinue use and see your healthcare practitioner. Standardized to be equivalent to 20 mg black cohosh (Cimicifuga racemosa) root and rhizome. Remifemin®, "Take 1 in the Morning and 1 in the Evening" and associated logo designs with butterfly and pill designs are registered trademarks and RemiSure™ is a trademark of Schaper & Brummer GmbH & Co. KG. This product has a tamper-evident foil pouch. Do not use if foil or pouch is punctured! Other Ingredients: lactose (milk), cellulose, potato starch, magnesium stearate, and natural peppermint flavor. Technical Data Description How Does It Work? Remifemin is a unique, proprietary, isopropanolic extract of black cohosh (Actaea racemosa; Cimicifuga racemosa) root and rhizome. The standardized black cohosh extract in Remifemin is backed by over 50 years of published clinical research. It is widely recommended by gynecologists as a safe and well-tolerated alternative to HRT for the management of menopausal symptoms.† Remifemin has been the subject of extensive clinical research and its efficacy in the management of menopausal symptoms has been established by several well-controlled clinical trials, as well as in open-label clinical studies.† Remifemin has been shown to safely and effectively reduce hot flashes, night sweats, related occasional sleeplessness, irritability, and mood swings associated with menopause.† Several clinical studies indicate that black cohosh, specifically Remifemin menopause and perimenopause relief, may be as effective as HRT in reducing hot flashes, night sweats, related occasional sleeplessness, irritability, and mood swings associated with menopause.†1-8 There have been numerous controlled clinical trials of Remifemin. For example, in 2005, Osmers and colleagues conducted a randomized, multicenter, double-blind clinical trial comparing the efficacy and tolerability of Remifemin in the treatment of menopausal symptoms compared with placebo.9 A total of 304 women were randomly allocated to receive 20 mg of Remifemin or matching placebo twice daily (BID) for 12 weeks. The results showed that women in the Remifemin group experienced a significant decrease in hot flashes. No significant adverse effects were reported. This clinical trial is characteristic of the results obtained from many such studies on Remifemin, summarized below. No other form of black cohosh has this level of published clinical validation. The following charts summarize findings in clinical studies of Remifemin: Double-Blind Studies Using Remifemin Author, Citation Subjects Dose Study Duration Study Population Primary Measures Study Conclusions Osmers R et al. Obstet Gynecol. 2005;105:1074–83. 304 20 mg BID 12 weeks Women = 45 with menopausal symptoms Menopause Rating Scale (hot flashes, psyche, soma, atrophy) Statistically significant improvement in menopause rating scale, especially in early menopause.†9 Liske E et al. J Womens Health Gend Based Med. 2002;11:163–74. 152 39 mg or 127.3 mg daily 24 weeks Peri- and post-menopausal women aged42 to 60 with menopausal symptoms Kupperman Index, Self-Rating Depression Scale (SDS) Statistically significant improvement in all scales at lower dose. No estrogenic changes in vaginal cytology or hormones.†10 Stoll W. Therapeutikon 1987;1:23–31. 80 32 mg BID 12 weeks Women aged 46 to 58 with climacteric complaints Kupperman index, HAM A scale, vaginal epithelium proliferation Statistically significant improvement in all scales. Some methodological concerns.†4 Bai W et al. Maturitas. 2007;58(1):31-4. 244 40 mg daily 12 weeks Menopausal women aged 40-60 years with menopausal symptoms Mann-Whitney values of the KMI and frequency of adverse events Statistically significant and clinically relevant efficacy, even for moderate to severe symptoms, with clearly superior safety.11 Nappi RE, et al. Gynecol Endocrinol. 2005 Jan;20(1):30–5. 64 40 mg daily 12 weeks Post-menopausal women aged Hot flashes, vasomotor and urogenital symptoms, occasional anxiety,  hormones. Remifemin relieved menopause symptoms as effectively as standard treatment.†12 Jacobson et al.J Clin Oncol. 2001 May 15;19(10): 2739–45. 85 20 mg BID 8 weeks Breast cancer patients aged 45 to 55 with two or more menopausal symptoms daily. 59  on tamoxifen. Hot flash diaries; FSH and LH. Treatment group not statistically different than placebo. Methodological and dose concerns.13 Pockaj BA et al. J Clin Oncol 2006; 24:2836–41. 132 20 mg BID Two 4-week periods Women ages 32-76 with hot flashes and a history of breast cancer, or perceived increased risk of breast cancer. Daily hot flash diary Treatment group not statistically different than placebo. Methodological concerns.14 In addition to these studies, there have been several open-label clinical trials demonstrating similar results. †7,8, 15-20 Recommendations Precautions How Is It Supplied? Storage Recommendations References Einer-Jensen N, Zhao J, Anderson K, Kristoffersen K. Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats. Maturitas. 1996;25:149-153. Lehmann-Willenbrock E, Reidel H. (Clinical and endocrinological examinations concerning therapy of climacteric symptoms following hysterectomy with remaining ovaries). Zent Bl Gynakol. 1988;110:611-618. Petho A. Menopausal complaints: change-over of a hormone treatment to a herbal gynecological remedy practicable? Arztliche Praxis. 1987;38, 47:1551-1553. Stoll W. Phytopharmacon influences atrophic vaginal epithelium: double-blind study: Cimicifuga vs estrogenic substances. Therapeutikon. 1987;1:1-14. Stolze H. An alternative to treat menopausal complaints. Gyne. 1982;1:14-16. Vorberg G. Treatment of menopausal complaints. Z. Allgemeinmed. 1984;13:626-629. Warnecke G. Influencing menopausal symptoms with a phytotherapeutic agent: successful therapy with Cimifuga mono-extract. Med Welt. 1985;36:871–4. Daiber W. Climacteric complaints: success without using hormones: a phytotherapeutic agent lessens hot flushes, sweating, and insomnia. Arztliche Praxis. 1983;65:1946-47. Osmers R, Friede M, Liske E, et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol. 2005;105:1074–83. Liske E, Hanggi W, Henneicke-von Zepelin HH, et al.Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med. 2002;11:163-74. Bai W, Henneicke-von Zepelin HH, Wang S, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas. 2007;58:31–41. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol. 2005;20:30-5. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001;19:2739–45. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC. J Clin Oncol 2006;24: 2836–41. Pockaj BA, Loprinzi CL, Sloan JA, et al. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest. 2004;22:515–21. Lehmann-Willenbrock E, Riedel HH. Clinical and endocrinological examinations concerning therapy of climacteric symptoms following hysterectomy with remaining ovaries. Zent Bl Gynäkol 1988;110:611-18. Petho A. Menopausal complaints: change-over of a hormone treatment to a herbal gynecological remedy practicable? Arztliche Praxis. 1987;38, 47:1551–53. Vorberg G. Treatment of menopausal complaints. Z. Allgemeinmed. 1984;13:626–9. Stolze H. An alternative to treat menopausal complaints. Gyne. 1982;1:14–16. Reame NE, Lukacs JL, Padmanabhan V et al. Black cohosh has central opioid activity in postmenopausal women:evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause. 2008;15:832–40.

† This statement has not been evaluated by the Food and Drug Administration.    This product is not intended to diagnose, treat, cure, or prevent any disease.

Click Below
to Check Price

Company | Site Map | Privacy & Security | Contact us | Send Feedback


© 1999-2013 Rite Care Pharmacy, Inc., All Rights Reserved
Use of this website signifies your agreement to the Terms of Use